Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Nov 13

PMID 34768548

Citations 1

Authors

Pawel Robak

Janusz Szemraj

Damian Mikulski

Izabela Drozdz

Karolina Juszczak

Dariusz Jarych

Malgorzata Misiewicz

Kacper Koscielny

Wojciech Fendler

Tadeusz Robak

Affiliations

Soon will be listed here.

Abstract

While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively evaluates the expression of POMP, PSMB5, NRF2, XBP1, cMAF and MAFb proteins in plasma cells isolated from the bone marrow of 39 MM patients treated with bortezomib-based regimens using an enzyme-linked immunosorbent assay (ELISA). The proteins were selected on the basis of previous laboratory and clinical studies in bortezomib-treated MM patients. It was found that the expression of the investigated proteins did not significantly differ between bortezomib-sensitive and bortezomib-refractory patients. However, the expression of some proteins correlated with overall survival (OS); this was significantly shorter in patients with higher POMP expression (HR 2.8, 95% CI: 1.1-7.0, = 0.0277) and longer in those with higher MAFB expression (HR 0.32, 95% CI: 0.13-0.80, = 0.0147). Our results indicate that a high expression of POMP and MAFB in MM plasma cells may serve as predictors of OS in MM patients treated with bortezomib-based regimens. However, further studies are needed to determine the role of these factors in effective strategies for improving anti-myeloma therapy.

Citing Articles

Transient receptor potential channels in multiple myeloma.

Meng L, Gu G, Bi L Oncol Lett. 2022; 23(4):108.

PMID: 35242236 PMC: 8848256. DOI: 10.3892/ol.2022.13228.

References

Yang Y, Chen Y, Saha M, Chen J, Evans K, Qiu L . Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia. 2014; 29(3):715-26. DOI: 10.1038/leu.2014.255. View

Pellett S, Tepp W, Johnson E, Sesardic D . Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons. J Pharmacol Toxicol Methods. 2017; 88(Pt 1):1-6. PMC: 5623611. DOI: 10.1016/j.vascn.2017.04.013. View

Chen D, Frezza M, Schmitt S, Kanwar J, Dou Q . Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011; 11(3):239-53. PMC: 3306611. DOI: 10.2174/156800911794519752. View

Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A . Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010; 24(8):1506-12. DOI: 10.1038/leu.2010.137. View

Moi P, Chan K, Asunis I, Cao A, Kan Y . Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A. 1994; 91(21):9926-30. PMC: 44930. DOI: 10.1073/pnas.91.21.9926. View

Durie B, Harousseau J, Miguel J, Blade J, Barlogie B, Anderson K . International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-73. DOI: 10.1038/sj.leu.2404284. View

Balsas P, Galan-Malo P, Marzo I, Naval J . Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. Leuk Res. 2011; 36(2):212-8. DOI: 10.1016/j.leukres.2011.09.011. View

Oerlemans R, Franke N, Assaraf Y, Cloos J, van Zantwijk I, Berkers C . Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008; 112(6):2489-99. DOI: 10.1182/blood-2007-08-104950. View

Anderson K, Kyle R, Rajkumar S, Stewart A, Weber D, Richardson P . Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2007; 22(2):231-9. DOI: 10.1038/sj.leu.2405016. View

10.

Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge M . Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015; 170(1):66-79. DOI: 10.1111/bjh.13394. View

11.

Katsuoka F, Yamamoto M . Small Maf proteins (MafF, MafG, MafK): History, structure and function. Gene. 2016; 586(2):197-205. PMC: 4911266. DOI: 10.1016/j.gene.2016.03.058. View

12.

Robak P, Jarych D, Mikulski D, Drozdz I, Weglowska E, Kotkowska A . The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers (Basel). 2021; 13(5). PMC: 7956525. DOI: 10.3390/cancers13050951. View

13.

Robak P, Drozdz I, Szemraj J, Robak T . Drug resistance in multiple myeloma. Cancer Treat Rev. 2018; 70:199-208. DOI: 10.1016/j.ctrv.2018.09.001. View

14.

Gandolfi S, Laubach J, Hideshima T, Chauhan D, Anderson K, Richardson P . The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017; 36(4):561-584. DOI: 10.1007/s10555-017-9707-8. View

15.

Shi C, Zhu Y, Bruins L, de Campos C, Stewart W, Braggio E . Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity. Mol Cancer Res. 2020; 18(10):1453-1464. PMC: 7541608. DOI: 10.1158/1541-7786.MCR-19-1026. View

16.

Sun Y, Abdul Aziz A, Bowles K, Rushworth S . High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Cancer Lett. 2017; 412:37-45. DOI: 10.1016/j.canlet.2017.10.005. View

17.

Wang S, Juan J, Zhang Z, Du Y, Xu Y, Tong J . Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. Cell Death Dis. 2017; 8(9):e3058. PMC: 5636991. DOI: 10.1038/cddis.2017.450. View

18.

Robak P, Robak T . Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs R D. 2019; 19(2):73-92. PMC: 6544598. DOI: 10.1007/s40268-019-0269-9. View

19.

Yadirgi G, Stickings P, Rajagopal S, Liu Y, Sesardic D . Immuno-detection of cleaved SNAP-25 from differentiated mouse embryonic stem cells provides a sensitive assay for determination of botulinum A toxin and antitoxin potency. J Immunol Methods. 2017; 451:90-99. DOI: 10.1016/j.jim.2017.09.007. View

20.

Bai J, Yang Y, Wang J, Zhang L, Wang F, He A . Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma. Clin Proteomics. 2019; 16:17. PMC: 6477722. DOI: 10.1186/s12014-019-9238-0. View